Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Hofman L, Satpathy AT, Stadtmauer EA, Cate JHD, Eyquem J, Fraietta JA, June CH, Chang HY, Ye CJ, Doudna JA. Cell. 2023 Oct 12; 186(21):4567-4585.e20. doi: 10.1016/j.cell.2023.08.041. 


From Penn Medicine Communications:

A new study published by a team from the University of California, Berkeley, with help from Penn Medicine collaborators including Carl June, MD, the Richard W. Vague Professor in Immunotherapy, found that the order steps are performed in CRISPR-Cas9 gene editing changes how well T cells are protected from a phenomenon known as chromosome loss.